TRCT
PGNX

Tower Research Capital (TRC)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Tower Research Capital (TRC)’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$1K – 4811
2019
Q3 		$1K Sell
100
-343
-77% -$1.71K ﹤0.01% 4005
2019
Q2 		$3K Sell
443
-1,947
-81% -$9.39K ﹤0.01% 3211
2019
Q1 		$11K Buy
2,390
+2,285
+2,176% +$10.3K ﹤0.01% 2655
2018
Q4 		$0 Sell
105
-72
-41% -$367 ﹤0.01% 4637
2018
Q3 		$1K Buy
+177
New +$1.36K ﹤0.01% 3674
2017
Q3 		– Sell
-252
Closed -$1.6K – 4313
2017
Q2 		$2K Sell
252
-3,602
-93% -$26.6K ﹤0.01% 2419
2017
Q1 		$36K Buy
3,854
+442
+13% +$4.41K ﹤0.01% 920
2016
Q4 		$29K Buy
3,412
+2,187
+179% +$16.2K ﹤0.01% 1823
2016
Q3 		$8K Buy
+1,225
New +$7.41K ﹤0.01% 2260
2016
Q2 		– Sell
-554
Closed -$2K – 5262
2016
Q1 		$2K Sell
554
-6,225
-92% -$27.7K ﹤0.01% 3512
2015
Q4 		$42K Buy
6,779
+6,179
+1,030% +$40.5K 0.01% 665
2015
Q3 		$3K Sell
600
-6,147
-91% -$47.2K ﹤0.01% 3210
2015
Q2 		$50K Sell
6,747
-4,391
-39% -$26.6K ﹤0.01% 1374
2015
Q1 		$66K Buy
11,138
+10,104
+977% +$63.6K 0.01% 1249
2014
Q4 		$8K Buy
+1,034
New +$6.19K ﹤0.01% 2381
2014
Q3 		– Sell
-2,041
Closed -$9K – 5092
2014
Q2 		$9K Sell
2,041
-1,093
-35% -$4.17K ﹤0.01% 2471
2014
Q1 		$13K Buy
+3,134
New +$16K ﹤0.01% 2376
2013
Q4 		– Sell
-5,687
Closed -$29K – 5087
2013
Q3 		$29K Buy
5,687
+5,487
+2,744% +$29.8K ﹤0.01% 2410
2013
Q2 		$1K Buy
+200
New +$897 ﹤0.01% 3780

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tower Research Capital (TRC)'s PGNX Position: Q4 2019 in Review

Tower Research Capital (TRC) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 100 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in PGNX in Q2 2013 and held it in 19 quarters. The position peaked at $66K in Q1 2015. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Tower Research Capital (TRC) reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 100 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Progenics Pharmaceuticals Inc position peaked at $66K in Q1 2015.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.